Telavancin for hospital-acquired pneumonia: Clinical response and 28-day survival

Authors

G. Ralph Corey, Duke UniversityFollow
Marin H. Kollef, Washington University School of Medicine in St. LouisFollow
Andrew F. Shorr, Washington Hospital Center
Ethan Rubinstein, University of Manitoba
Martin E. Stryjewski, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
Alan Hopkins, Theravance, Inc.
Steven L. Barriere, Theravance, Inc.

Journal

Antimicrobial Agents and Chemotherapy

Publication Date

2014

Volume

58

Issue

4

Inclusive Pages

2030-2037

Document Type

Open Access Publication

DOI

10.1128/AAC.02330-13

Rights and Permissions

Corey, G. R., Kollef, M. H., Shorr, A. F., Rubinstein, E., Stryjewski, M. E., Hopkins, A., & Barriere, S. L. (2014). Telavancin for hospital-acquired pneumonia: Clinical response and 28-day survival. Antimicrobial Agents and Chemotherapy, 58(4), 2030-2037. DOI: 10.1128/AAC.02330-13

Recommended Citation

Corey, G. Ralph; Kollef, Marin H.; Shorr, Andrew F.; Rubinstein, Ethan; Stryjewski, Martin E.; Hopkins, Alan; and Barriere, Steven L., "Telavancin for hospital-acquired pneumonia: Clinical response and 28-day survival." Antimicrobial Agents and Chemotherapy. 58, 4. 2030-2037. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2722